Cancer drugmaker Revolution Medicines says sale not a priority

Revolution Medicines said it is not actively prioritizing a sale, even as attention builds around its pancreatic cancer drug daraxonrasib and reported takeover interest from larger drugmakers.

Chief Executive Mark Goldsmith told the Financial Times that acquisition is not a high-priority area for the company. The comments come as investors weigh whether the biotechnology company will remain independent or eventually become a target after a run of clinical and regulatory milestones around its lead program.

Daraxonrasib has become one of the closely watched experimental cancer drugs in development because it targets KRAS, a key cancer driver in the vast majority of pancreatic cancers. That scientific profile has made Revolution Medicines a focal point in both the cancer drug race and the broader pharmaceutical deal market.

Clinical momentum

The current takeover chatter is being overshadowed by the drug’s clinical progress. Recent reporting on Revolution Medicines’ phase 3 data described daraxonrasib as producing a meaningful survival benefit compared with chemotherapy.

The Financial Times said the study showed significantly longer overall survival and progression-free survival than chemotherapy. Other reports cited the median overall survival result as 13.2 months for daraxonrasib versus 6.7 months for chemotherapy.

Those results have helped put the drug among the most closely watched experimental therapies in pancreatic cancer, a disease that remains one of the deadliest cancers and has historically seen limited treatment progress.

The response from oncologists at the ASCO presentation was notably strong, according to earlier reporting, adding to the sense that daraxonrasib could become an important therapy if the data hold up through the rest of the regulatory process.

FDA access

The U.S. Food and Drug Administration has already granted expanded access to daraxonrasib for eligible pancreatic cancer patients while the drug remains under review.

That program is limited to patients who have already received conventional treatment. The company said in a statement quoted by The Washington Post that it is moving as quickly as possible to ensure safe and equitable access for eligible U.S. patients.

Revolution Medicines also said the drug will be provided at no cost in the expanded-access program. The company has described daraxonrasib as an oral, daily pill regimen taken as three pills per day.

The access decision matters for patients because it creates a route to the drug before full approval, while also signaling that regulators and the company view the therapy as serious enough to make available ahead of the final decision.

Deal pressure

The Financial Times reported that larger drugmakers have shown interest in Revolution Medicines, including Merck. That interest fits a wider pattern in pharmaceuticals, where big companies are searching for late-stage assets to help offset looming patent losses.

Revolution Medicines went public in 2020 and has gained value on the strength of daraxonrasib’s potential. As the clinical case has strengthened, the company has also become a more visible strategic asset.

Goldsmith’s comments suggest the company wants the market to focus on the drug itself rather than on a near-term sale process. For now, the message is that independence remains the default posture.

What comes next

The next major milestones are the FDA review path for daraxonrasib and any additional updates on expanded access for eligible patients.

Investors will also be watching whether Revolution Medicines provides more detail on the full phase 3 dataset, publishes it in a medical journal or presents it at a conference, and whether the company offers any formal guidance on strategic alternatives.

If the drug continues to show strong clinical performance, the tension between remaining independent and responding to eventual takeover pressure is likely to stay part of the story.